InvestorsObserver

GTBP GT Biopharma Inc

$3.35 $0.00 (-0.15%)
15 Minute Delayed Price Enable Real-Time Price
Overall NA

GTBP Stock Analysis Overview

No Overall Rank data available for GT Biopharma Inc (GTBP)

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

GTBP Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

GTBP Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

GTBP Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

GTBP Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

GTBP Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

GTBP Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

GTBP Stock Analysis Overview

No Overall Rank data available for GT Biopharma Inc (GTBP)

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full GTBP report

GTBP Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

GTBP Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

GTBP Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

GTBP Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

GTBP Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

GTBP Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

GT Biopharma Inc (GTBP) Analyst Forecast

GTBP Price, Volume, Earnings, and Dividend Date

  • Last Price $3.35
  • Previous Close $3.35
  • Change $0.00
  • Open $3.60
  • Volume 10,336
  • Avg. Volume (100-day) 10,480
  • Market Cap 4,618,217
  • Days Range 3.2125 - 3.6
  • 52-week Range 3.21 - 16.11
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date 05/20/24
  • Sector
  • Industry
  • Avg. Analyst Rec. Premium
  • Beta
  • PEG Ratio

GT Biopharma Inc (GTBP) Company Description

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

GT Biopharma Inc (GTBP) Stock Chart